@ApolloTriCoat 3 steps ahead
Annual production capacity 2.5L tonnes
35+ years experience
1-week cycle time ( order booking to supply)

Brands
Apollo chaukhat
Apollo elegant
Apollo signature
Apollo steel plank
Apollo Wondoor
Mk cap 2337 cr
P/E 37.7
BV 76.4
ROCE 26.5
ROE 26.1
Interest coverage 9.12
EY 3.99%
P/S 2.44
D/E 0.25
PEG 0.22
EVEBIDTA 21.8

Promoter holding
Dec 19 61.77
Sep 20 62.56
Q2 fy21 investor presentation

Q2fy20 vol 60823 ton
121% YoY increase
Ebidta 373 mn ,up 142%
Ebidta per ton 6137 ,up 10% YoY
Ebidta margin 11.3%
Net profit 238 mn,153 % up YoY
ROCE 30.7% ,Fy20 20.2
Capacity 350000 as on Sep 20

#nifty #sensex #apollotricoat
Q2 sales volume sustained after recovery in May 20,margins up supported by cost manag
Net debt down to 0.7 bn from 1.1 bn in Fy20
D/E 0.3x from 0.5 in FY20
Annual capacity enhanced to 350kton from 250kton
Capex funded by internal accrual
Q2 capacity utilization 70%
#stocks
Product portfolio
Chaukhat - steel door frames in affordable & high end housing,commercial buildings, industrial sheds

Home beautification
Elegant - Designer hand railing
Signature - Designer roofing,Fencing ,steel furniture
Plank - Staircase steps ceilings,Truck bodies
Operational performance

Brand/ Q2fy20/Q2fy21/Annual capacity

Signature/15635/17968/125000
Chaukhat/6612/15185/75000
Elegant/4962/26749/125000
Plank/320/921/25000
Total /27529/60823/350000
Financial performance

Q2fy20 / Q2fy21

Revenue(Rsm) 1537/3305
Vol (000's ton) 27.5/60.8
Ebidta (Rsm) 154/373
Ebidta/ ton (Rs) 5603/ 6137
Ebidta margin % 10/11.3
Net profit (Rsm) 94/238
Cash profit 116/279

D/E 0.3
Debt/Ebidta 1.2
Int coverage 9.6
Financial highlights
Fy20 / H1Fy21

Cash 48/5
Receivables 379/104
Inventories 768/728
Trade payables 1124/899
Debt 1126/693

@ApolloTriCoat
@tycoonmindset05 @thescorpionphil
@nid_rockz

Unroll
@threadreaderapp
Compile
@threader_app

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with TheMarket🐝

TheMarket🐝 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @BullsforBears

18 Nov
#hindustanfoods
Q2fy21 & H1fy21 investor presentation

Key developments
Additional investment 150 cr mfg personal & home care products
Merger of beverage plant Mysuru in progress
New plant for Surface cleaner, Silvasa to start in Feb 21
Merger Malta beverages plant Coimbatore
Long term contract mfture Disinfectant toilet cleaner at Silvasa facility,commenced Sep 20,capacity 100KL/day
Goal of 2000 crs topline by 2022

Gross block Sep 20 - 332 crs
Revenue H1fy21 - 522 cr,64% growth YoY
Ebidta H1fy21 - 37.1 cr 54% growth YoY
PAT 12.6 cr ,up 37%
#Nifty
Operating cash flow 13.4 cr,up 24% YOY
EPS 5.96 for H1fy21,up 19%

Financial highlights
Q2fy21 / Q2fy20
Revenue 319/172
Ebidta 22 /12.8
PAT 8.4/ 4.9
Operating cash flow 13.5 /10.8

H1fy21 / H1fy20
Revenue 521 /317
Ebidta 37.1/ 24.1
PAT 12.6/ 9.2
Read 16 tweets
16 Nov
@NeulandLabs investor presentation Q2fy21

Operational highlights
H1fy21
Revenue increased 21.7% led by growth in all 3 segments
Ebidta margin up 480bps to 16.9%
PBT margin up 550bps ,PAT margin up 430bps
Q2fy21
Revenue up 29.6%,balanced growth of GDS & CMS
Prime segment saw high growth of levetericetam,continued growth Mirtazapine,Lavetalol
Speciality business stable Q led by Deferasirox,Entacapone & Ezetimibe
CMS saw vol growth in baseline projects
Unit 3 started generating rev
Filed DMF for Edaravone with USFDA

Q2fy21/Q2fy20 cr
Revenue 242/186
Ebidta 41/25
PAT 21.3/8.6
EPS 16.6/6.68

H1fy21/H1fy20
Revenue 448/368
Ebidta 74.8/44.5
PAT 36.4/14.2
EPS 28.37/11.06

CMS Rev split
Q2fy21
Commercial 50
Development 27
Q2fy20
Comm 40
Devlpmnt 9

#Nifty #sensex
Read 11 tweets
10 Nov
#balajiamines investor presentation Nov 20

H1fy21 / H1fy20 in cr
Revenue 496/ 467
Ebidta 125/87.96
PAT 82/54
Sales vols up by 8.3% ,from 21376 to 23150 MT YoY

Increased volume off take
Amines 5094 MT
Amine derivative 9916
Speciality chemicals 8140 MT

#sensex #Nifty #stocks
Demand for Acetonitrile,DMF,NEP,DMA,TEA continues to remain elevated ,intermediates for Covid 19 drugs
Debottlenecking of Acetonitrile plant commenced ,production output to jump to 18-20 tons from current 9 tons/day
Antidumping duty will lead to higher capacity utilization of DMF
Subsidiary Balaji speciality pvt chemicals ltd received REACH certification from EU for Diethylene triamine,sales runrate of 10 crs/month
Ethylamines mfg commence end of FY21,DMC to begin in Fy22

Expansion plans
Acetonitrile - installed capacity 9000 TPA, clearance for 18000TPA
Read 11 tweets
9 Nov
#amberenterprises Q2fy20 investor presentation
Import of ACs with refrigerants is Prohibited, 4000 crs of RAC were being imported in India
Prohibition will enhance local manufacturing, Amber well placed as a one stop provider for HVAC industry

#nifty #sensex #StockMarket
Strong balance sheet, large client base ,increased penetration in HVAC industry to drive growth
Railway & metro business impacted due to covid,however order book strong
Vocal for local to boost India mftng
China plus 1 to drive export mkt
Increased focus on R & D
#stocks
Q2fy21 / Q2fy20 in crs
Revenue 623/408
Operating Ebidta 39 /22
PAT 12/3
Pent up demand in Q1fy21 led to clearance of channel inventory
Demand uptick for ACs in tier 2,3 cities
Import ban has led to enquiries from large players
Business to achieve normalcy in H2fy21
Read 5 tweets
8 Nov
@MarksansPharma #marksanspharma Investor presentation Sep ' 20

Revenue growth 36.3%
Ebidta growth 109.5%
PAT growth 95.4%
Cash 154.4 crores
ROCE - Mar'18 12.1% ,Sep'20 29.4%
ROE - Mar'18 7.5% ,Sep 20 22.8%
Net debt to Ebidta - Mar'18 0.89 ,Sep 20 -0.48
Q2fy21 / Q2fy20 in cr
Revenue 360/264
Ebidta 86.8/41.4
Ebidta margin 24.1/15.7%
PAT 50.7/26
PAT margin 14.1/9.8%

H1fy21 /H1fy20
Revenue 691/511
Ebidta 157/76
Ebidta margin 22.7/14.9%
PAT 100/48.5
PAT margin 14.5/9.5%

#nifty #sensex #StockMarket #stocks #markets
95% of company revenues came from regulated overseas mkt

Formulation business from Europe,UK 286cr compared to 225cr last year,growth 27%
US & North America growth 48.7% to 302.5 cr in H1fy21
Australia & NZ revenue 69.4 cr in H1fy21 ,growth of 12.1% YOY
#pharma
Read 14 tweets
7 Nov
@TataConsumer
Brands
Tata salt largest salt brand in India
Tata tea 2nd largest tea brand in India
Tetley 4th largest tea brand in UK & largest in Canada
Himalayan 1st natural mineral water brand in India
Tata sampann Leading national brand
8'0 clock 4th in R&G coffee in US
9.6K crore consolidated revenue in FY20, current MKT cap 47K cr
Reach - 200 mn households in India,distribution 2.2 mn retail outlets
Among top 10 FMCG companies in India
2250 employees
Number 2 branded tea player globally
Aspiring to get a larger share of Fmcg mkt in India
Executive summary
Cons revenue grew 19% to 2781cr,strong growth India business
Cons Ebidta grew 26% ,INR 402 cr
Packaged beverage business India grew 29%
India food business grew 13%
Branded Int beverage business grew 11%
Cons PBT for the quarter higher ht 31% ,345 cr
#Nifty
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!